Study S001851

A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) as Two Subcutaneous Presentations in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07226778
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 348
Start: 2025-10-10
Primary completion: 2026-05-28
Lead sponsor: Amgen
Conditions: Overweight; Obesity
Interventions: DRUG:Maridebart Cafraglutide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Area Under the Plasma Concentration Time Curve from Time Zero to Infinity (AUCinf) of Maridebart Cafraglutide [Up to Day 120]
Area Under the Plasma Concentration Time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of Maridebart Cafraglutide [Up to Day 120]
Maximum Observed Plasma Concentration (Cmax) of Maridebart Cafraglutide [Up to Day 120]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.